Wildy Logo
(020) 7242 5778
enquiries@wildy.com

Book of the Month

Cover of Spencer Bower and Handley: Res Judicata

Spencer Bower and Handley: Res Judicata

Price: £449.99

Lord Denning: Life, Law and Legacy



  


Welcome to Wildys

Watch


NEW EDITION Pre-order The Law of Rights of Light 2nd ed



 Jonathan Karas


Offers for Newly Called Barristers & Students

Special Discounts for Newly Called & Students

Read More ...


Secondhand & Out of Print

Browse Secondhand Online

Read More...


Drugs, Patents and Policy: A Contextual Study of Hong Kong


ISBN13: 9781108796125
Published: December 2019
Publisher: Cambridge University Press
Country of Publication: UK
Format: Paperback (Hardback in 2018)
Price: £23.99
Hardback edition , ISBN13 9781316512340



Despatched in 6 to 8 days.

In pharmaceutical patent law, the problem of lack of policy direction and inappropriate legal framework is widespread - particularly among jurisdictions with little to no pharmaceutical research or manufacturing. This book aims to inform public policy and influence debate through a comprehensive review of Hong Kong's pharmaceutical patent law. By demonstrating the need for a holistic review of pharmaceutical patent laws and evaluating Hong Kong's system in light of health policy, economic and social factors, Bryan Mercurio recommends changes to the legal framework and constructs a more efficient and effective system for Hong Kong. He thoroughly evaluates the international framework and best practice models to offer a global perspective to each issue before providing local context in the analysis. While the focus of the book is Hong Kong, the analysis on pharmaceutical patent law and policy extends to other jurisdictions facing issues on reforming their national system.

Subjects:
Other Jurisdictions , Hong Kong
Contents:
1. Introduction
2. The contextual framework of Hong Kong's pharmaceutical patent laws and policy
3. Standards of patentability
4. Extension of patent terms for pharmaceutical products
5. Exceptions to exclusive rights
6. Test data exclusivity
7. Patent linkage
8. Conclusion